YOLFTbeta
Fulcrum Therapeutics Inc

Fulcrum Therapeutics Inc

FULC · NASDAQ · Healthcare / Biotechnology

3.77USD+0.09 (+2.45%)

Price History

Full chart

Market Stats

Previous Close3.68
Open3.77
Day Range3.73 – 3.80
52-Week Range2.83 – 15.74
Volume1.36M
Market Cap285.35M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.21
Dividend Yield0.00%
Beta2.58
50-Day Avg3.78
200-Day Avg6.90

About

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Alexander C. Sapir
  • Employees9
  • Headquarters26 Landsdowne Street, Cambridge, MA, United States, 02139, USA
  • Websitehttps://www.fulcrumtx.com

Leadership

  • Mr. Alexander C. SapirCEO, President & Director · b. 1967
  • Mr. Alan A. Musso C.M.A., CPACFO, Treasurer & Principal Accounting Officer · b. 1962
  • Mr. Curtis G. Oltmans J.D.Chief Legal Officer, Head of External Affairs & Corporate Secretary · b. 1963
  • Dr. Bradley E. Bernstein M.D., Ph.D.Founder
  • Dr. Michael R. GreenFounder
  • Dr. Rudolf Jaenisch M.D., Ph.D.Founder
  • Dr. Tsun-Huei Lee M.D., Ph.D.Founder · b. 1964
  • Dr. Danny ReinbergFounder
  • Dr. Iain Fraser DPHILSenior Vice President of Early Development
  • Bobby Riehle Ph.D.Head of Program Strategy & Vice President

Financials

Income Statement

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00750.00K8.82M19.16M6.34M2.81M80.00M0
Growth (%)---+1076.40%+117.19%-66.90%-55.77%+2752.05%-100.00%
Cost of Revenue715.00K1.34M2.05M2.38M2.52M76.78M71.80M63.39M1.39M
Gross Profit-715.00K-1.34M-2.05M8.82M19.16M-70.44M-69.00M16.61M-1.39M
Gross Margin---273.73%100.00%100.00%-1110.69%-2459.75%20.77%-
Operating Expense22.28M32.15M82.16M80.43M100.22M42.12M41.67M38.51M83.38M
Operating Income-22.99M-33.50M-84.22M-71.61M-81.05M-112.56M-110.66M-21.90M-84.77M
Operating Margin---11228.93%-811.64%-422.97%-1774.85%-3945.24%-27.37%-
EBITDA-22.28M-32.15M-82.16M-69.23M-78.54M-109.72M-95.16M-18.24M-73.49M
EBITDA Margin---10955.20%-784.68%-409.85%-1730.05%-3392.62%-22.80%-
Net Income-22.96M-32.59M-79.11M-68.44M-78.33M-109.87M-97.33M-9.72M-74.88M
Net Income Margin---10548.40%-775.70%-408.77%-1732.43%-3470.05%-12.16%-
R&D18.49M25.18M71.07M59.04M69.70M76.78M71.80M63.39M56.10M
R&D as % of Total Revenue--9476.27%669.18%363.73%1210.69%2559.75%79.23%-
Interest Expense00002.72M2.69M---
Interest Expense % of Total Revenue--0.00%0.00%14.20%42.42%---

Balance Sheet

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.34M85.77M110.44M129.58M235.00M226.69M257.69M260.72M366.28M
Total Liabilities3.02M9.77M23.29M34.40M23.46M27.74M22.50M17.68M17.28M
Total Equity1.32M76.00M87.15M95.18M211.54M198.94M235.19M243.03M349.00M
Cash407.00K72.80M96.71M57.05M35.41M35.10M25.56M58.21M197.53M
Total Debt34.59M46.00K50.00K17.00K469.00K13.42M10.82M8.63M6.44M
Net Debt34.18M-72.75M-96.66M-57.03M-35.41M-21.68M-14.74M-49.58M-191.09M

Cash Flow

Currency: USD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-20.07M-22.56M-39.48M-53.66M-78.48M-97.05M-90.97M-2.22M-60.06M
Investing Cash Flow-1.91M-8.98M-944.00K-57.14M-129.67M12.41M-36.69M32.23M30.72M
Financing Cash Flow17.66M105.03M64.34M71.13M186.51M84.32M118.12M2.75M168.67M
Capital Expenditure1.91M8.98M853.00K1.34M1.71M1.96M508.00K278.00K314.00K
Free Cash Flow-21.98M-31.54M-40.34M-55.00M-80.19M-99.01M-91.47M-2.50M-60.38M
Dividends Paid00-68.52M-----
FCF to OCF109.50%139.81%102.16%102.50%102.18%102.02%100.56%112.53%100.52%
Dividend Paid to FCF0.00%0.00%--124.58%-----

Earnings

Report DateMay 29, 2019Aug 26, 2019Nov 14, 2019Mar 5, 2020May 13, 2020Aug 11, 2020Nov 10, 2020Mar 4, 2021May 6, 2021Aug 10, 2021Nov 4, 2021Mar 3, 2022May 9, 2022Aug 11, 2022Nov 8, 2022Mar 9, 2023May 15, 2023Aug 3, 2023Nov 7, 2023Feb 27, 2024May 13, 2024Jul 31, 2024Nov 13, 2024Feb 25, 2025May 1, 2025Jul 29, 2025Oct 29, 2025Feb 26, 2026Apr 27, 2026Aug 4, 2026Nov 4, 2026
EPS Estimate0.00-0.75-0.72-0.88-0.75-0.75-0.64-0.72-0.66-0.65-0.65-0.73-0.63-0.66-0.61-0.49-0.46-0.44-0.44-0.43-0.440.06-0.40-0.29-0.29-0.29-0.29-0.31-0.30-0.21-0.10
EPS Actual-0.31-0.71-0.97-0.71-0.81-0.66-0.70-0.64-0.54-0.60-0.57-0.58-0.64-0.83-0.50-0.50-0.41-0.38-0.39-0.40-0.430.87-0.46-0.31-0.28-0.28-0.31-0.31-0.25-0.29-
Surprise-5.33%-34.72%19.32%-8.00%12.00%-9.38%11.11%18.18%7.69%12.31%20.55%-1.59%-25.76%18.03%-2.04%10.87%13.64%11.36%6.98%2.27%1350.00%-15.00%-7.53%3.45%3.45%-6.90%-1.47%16.67%-36.48%-
Timing-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market--

Key Statistics & Ratios

Market Cap285.35M
Enterprise Value-22.87M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.66
Price / Book0.94
EPS-1.21
Book Value4.07
Revenue (TTM)0
Gross Profit (TTM)-56.10M
EBITDA-85.40M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-32.38%
Return on Assets-19.59%
Shares Outstanding76.30M
Shares Float63.49M
Beta2.58
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 7 analystsTarget 3.67
  • Strong Buy
    2
  • Buy
    1
  • Hold
    3
  • Sell
    1

Ownership Breakdown

Institutions
103.51%
Insiders
3.35%
Retail / Other
0.00%

Top Institutional Holders

  • Suvretta Capital Management, LLC
    6.56M8.60%
  • EcoR1 Capital, LLC
    6.55M8.58%
  • RA Capital Management, LLC
    6.05M7.93%
  • BlackRock Inc
    5.39M7.07%
  • BRAIDWELL LP
    3.13M4.11%
  • Nantahala Capital Management, LLC
    3.05M4.00%
  • D. E. Shaw & Co LP
    3.04M3.99%
  • Citadel Advisors Llc
    2.70M3.54%
  • Vanguard Capital Management, LLC
    2.69M3.53%
  • Siren, L.L.C.
    2.35M3.08%
  • Point72 Asset Management, L.P.
    2.07M2.72%
  • Adage Capital Partners Gp LLC
    2.00M2.62%
  • GSK PLC
    1.79M2.34%
  • Balyasny Asset Management LLC
    1.78M2.33%
  • State Street Corp
    1.55M2.03%
  • Geode Capital Management, LLC
    1.49M1.95%
  • Millennium Management LLC
    1.49M1.95%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.07M2.72%
  • iShares Russell 2000 ETF
    1.53M2.00%
  • BlackRock Advantage Small Cap Core Instl
    1.42M1.87%